SAT0384 Multireader Reliability Using Us in Salivary Glands: An International Web Exercice to Evaluate a New Us Scoring (NUSC) in Primary Sjogren Syndrome

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 798.2-798
Author(s):  
S. Jousse ◽  
E. Nowak ◽  
E. Theander ◽  
A. Hocevar ◽  
M. Jonsson ◽  
...  
Keyword(s):  
Salivary Glands ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Primary Sjögren Syndrome

Role of Fractalkine in the Pathogenesis of Primary Sjögren Syndrome: Increased Serum Levels of Fractalkine, Its Expression in Labial Salivary Glands, and the Association with Clinical Manifestations

2014 ◽  
Vol 41 (12) ◽  
pp. 2425-2438 ◽  
Author(s):  
Jae Ho Lee ◽  
Seung-Ki Kwok ◽  
Seung Min Jung ◽  
Jennifer Lee ◽  
Jae-Seon Lee ◽  
...  
Keyword(s):  
Epithelial Cells ◽  
Confocal Microscopy ◽  
Salivary Glands ◽  
Proinflammatory Cytokines ◽  
Sjögren Syndrome ◽  
Control Group ◽  
Sjogren Syndrome ◽  
Clinical Effects ◽  
Extraglandular Manifestations ◽  
Primary Sjögren Syndrome

Objective.To investigate the expression of fractalkine and identify the clinical effects of fractalkine and its receptor (CX3CR1) in patients with primary Sjögren syndrome (pSS).Methods.Serum fractalkine levels were determined by ELISA. Immunohistochemical staining was done to compare the expression of fractalkine and CX3CR1 between salivary glands (SG) of patients with SS and controls. The cells to be merged with fractalkine were evaluated by confocal microscopy. Type of CX3CR1-expressing cells among infiltrating lymphocytes in SG was analyzed by confocal microscopy. Further, associations among fractalkine, proinflammatory cytokines, and clinical profiles were investigated.Results.Serum fractalkine levels in patients with pSS were higher than those in the control group (p = 0.026). SG expression of fractalkine and its receptor was upregulated in patients with pSS compared to that in the controls by immunohistochemistry. Higher histological grade was associated with more fractalkine-positive cells per total epithelial cells. Epithelial cells were the main fractalkine-expressing cell type in the SG. Serum fractalkine levels were significantly correlated with proinflammatory cytokines levels (interleukin 17: r = 0.685, p = 0.029; tumor necrosis factor-α: r = 0.444, p = 0.003), antinuclear antibody (r = 0.349, p = 0.022), and immunoglobulin G levels (r = 0.325, p = 0.044). Serum fractalkine levels in patients with extraglandular manifestations of pSS were significantly higher than in those without extraglandular manifestations (p = 0.026).Conclusion.Fractalkine and CX3CR1 may play a role in the pathogenesis of pSS, including extraglandular manifestations.

The Interleukin 33/ST2 Axis in Patients with Primary Sjögren Syndrome: Expression in Serum and Salivary Glands, and the Clinical Association

2014 ◽  
Vol 42 (2) ◽  
pp. 264-271 ◽  
Author(s):  
Seung Min Jung ◽  
Jaeseon Lee ◽  
Seung Ye Baek ◽  
Jae Ho Lee ◽  
Jennifer Lee ◽  
...  
Keyword(s):  
Salivary Glands ◽  
Activity Index ◽  
Disease Activity Index ◽  
Serum Levels ◽  
Interferon Γ ◽  
Sjögren Syndrome ◽  
Epithelial Cell Line ◽  
Sjogren Syndrome ◽  
Interleukin 33 ◽  
Primary Sjögren Syndrome

Objective.To evaluate the expression of interleukin 33 (IL-33) and its receptor in sera and salivary tissues of patients with primary Sjögren syndrome (pSS), and to investigate the association with clinical profiles.Methods.Serum IL-33 and soluble ST2 (sST2) of 55 patients with pSS and 48 controls were determined by ELISA and assessed for clinical correlation. The expression of IL-33/ST2 in salivary tissues was investigated by immunohistochemical staining and was further characterized by confocal microscopy. We also measured IL-33 production in salivary glandular epithelial cells by proinflammatory stimuli.Results.Serum levels of IL-33 and sST2 were higher in patients with pSS compared to those in controls (p = 0.018 and p < 0.0001, respectively). Among patients with pSS, sST2 concentration was associated with thrombocytopenia (p = 0.029) and correlated with disease duration (p = 0.013) and the European League Against Rheumatism Sjögren Syndrome Disease Activity Index (p = 0.042). The expression of IL-33 and ST2 was elevated in salivary glands of patients with pSS with grade 2 inflammation, and diminished in advanced inflammation. In patients with pSS, IL-33 was mainly observed in epithelial and endothelial cells of glandular tissue. The production of IL-33 mRNA by salivary gland epithelial cell line increased under stimulation with interferon-γ.Conclusion.The expression of IL-33 and its receptor was elevated in sera and salivary tissues of patients with pSS. These results suggest that the IL-33/ST2 axis might have a role in the pathogenesis of pSS.

Virtual Touch Quantification of the Salivary Glands for Diagnosis of Primary Sjögren Syndrome

2016 ◽  
Vol 35 (12) ◽  
pp. 2607-2613 ◽  
Author(s):  
Shaoqi Chen ◽  
Yukai Wang ◽  
Shaoxing Chen ◽  
Qiulin Wu ◽  
Shigao Chen
Keyword(s):  
Salivary Glands ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Primary Sjögren Syndrome

scholarly journals Expression of Podoplanin in Minor Salivary Glands Increases in Primary Sjögren Syndrome

2013 ◽  
Vol 40 (12) ◽  
pp. 2100-2102 ◽  
Author(s):  
VELI YAZISIZ ◽  
AHMET BEHLUL ◽  
ŞERMIN TÜLAY E. BASAK ◽  
FATIH BORLU
Keyword(s):  
Salivary Glands ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Minor Salivary Glands ◽  
Primary Sjögren Syndrome

scholarly journals Increased frequency of CD16+ monocytes and the presence of activated dendritic cells in salivary glands in primary Sjögren syndrome

2008 ◽  
Vol 68 (3) ◽  
pp. 420-426 ◽  
Author(s):  
M E Wildenberg ◽  
J M C Welzen-Coppens ◽  
C G van Helden-Meeuwsen ◽  
H Bootsma ◽  
A Vissink ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Salivary Glands ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Monocyte Subset ◽  
Monocyte Subsets ◽  
Primary Sjögren Syndrome ◽  
Normal Expression ◽  
Mature Mouse

Objectives:In the salivary glands of patients with primary Sjögren Syndrome (pSjS) an accumulation of dendritic cells (DCs) is seen, which is thought to play a role in stimulating local inflammation. Aberrancies in subsets of monocytes, generally considered the blood precursors for DCs, may play a role in this accumulation of DCs. This study is aimed at determining the level of mature CD14lowCD16+ monocytes in pSjS and their contribution to the accumulation of DCs in pSjS.Methods:Levels of mature and immature monocytes in patients with pSjS (n = 19) and controls (n = 15) were analysed by flow cytometry. The reverse transmigration system was used for generation of DCs generated from monocyte subsets. The phenotype of DCs in pSjS salivary glands was analysed using immunohistochemistry. In vivo tracking of monocyte subsets was performed in a mouse model.Results:Increased levels of mature CD14lowCD16+ monocytes were found in patients with pSjS (mean (SD) 14.5 (5.5)% vs 11.4 (3.4)%). These cells showed normal expression of chemokine receptor and adhesion molecules. Mature monocytes partly developed into DC-lysosome-associated membrane glycoprotein (LAMP)+ (19.6 (7.5)%) and CD83+ (16 (9)%) DCs, markers also expressed by DCs in pSjS salivary glands. Monocyte tracking in the non-obese diabetic (NOD) mouse showed that the homologue population of mature mouse monocytes migrated to the salivary glands, and preferentially developed into CD11c+ DCs in vivo.Conclusions:Mature monocytes are increased in pSjS and patient and mouse data support a model where this mature monocyte subset migrates to the salivary glands and develops into DCs.

THU0267 Ultrasonographic Salivary Glands Response to Rituximab in Primary SjöGren Syndrome Patients (Tears Sononographic Study)

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A255.3-A256
Author(s):  
S. Jousse-Joulin ◽  
V. Devauchelle-Pensec ◽  
D. Cornec ◽  
T. Marhadour ◽  
L. Bressolette ◽  
...  
Keyword(s):  
Salivary Glands ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Primary Sjögren Syndrome

Primary Sjogren Syndrome: Clinical Features and Management

2017 ◽  
Author(s):  
Stephanie L Giattino ◽  
E William St. Clair
Keyword(s):  
B Cell ◽  
Salivary Glands ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Sjogren's Syndrome ◽  
Sjögren Syndrome ◽  
Dry Mouth ◽  
Sjogren Syndrome ◽  
Dry Eyes ◽  
Primary Sjögren Syndrome

Primary Sjögren syndrome (SS) is a chronic inflammatory disease affecting the lacrimal and salivary glands, resulting in dry eyes and dry mouth. It may also lead to systemic manifestations, including fatigue, arthritis, lung involvement, kidney disease, neuropathy, and vasculitis, and predisposes to B cell lymphoma. The diagnosis of primary SS is based on a composite of clinical, serologic, and pathologic features, namely, objective evidence of dry eyes and dry mouth and either a positive test for anti-SSA (Ro) antibodies or a positive labial salivary gland biopsy. Primary SS may be confused with other conditions affecting the lacrimal and salivary glands, such as chronic hepatitis C virus infection, sarcoidosis, and a new entity, IgG4-related disease. The management of patients with primary SS is largely symptomatic and consists of tear supplementation, regular dental hygiene, and liberal use of moisturizers. Cyclosporine 0.05% ophthalmic emulsion and lifitegrast 5% ophthalmic solution are approved agents for the treatment of dry eyes. Two oral secretagogues, pilocarpine and cevimeline, have been shown in trials to significantly reduce the symptoms of dry eyes and dry mouth. Although hydroxychloroquine may reduce fatigue and joint pain, the results of a randomized controlled trial failed to confirm its efficacy in this clinical setting. More serious organ system involvement may be managed with corticosteroids and other immunomodulatory drugs. Although no disease-modifying drugs are currently approved for the treatment of primary SS, a robust pipeline of promising therapies for this disease is currently in development. This review contains 3 figures, 5 tables, and 69 references. Key words: anti-Ro/SSA antibodies, B cell lymphoma, classification criteria, EULAR Sjögren’s syndrome Patient Reported Index (ESSPRI), EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI), hydroxychloroquine,  keratoconjunctivitis sicca, rituximab, Sjögren syndrome

Sign in / Sign up

Export Citation Format

Share Document